CuraGen Corporation and TopoTarget A/S announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for the
Archive for the 'CuraGen' Category
Last update: April 01, 2019. 03:30:08 pm.